Pharmacological management of osteogenesis

Clinics

Volumn 69, Issue 6, 2014, Pages 438-446

  Nardone, Valeria ^a   D'Asta, Federica ^a   Brandi, Maria Luisa ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Antiresorptive Drugs; Bone formation; Osteoblasts; Osteogenesis; RANKL inhibitors

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; DENOSUMAB; MONOCLONAL ANTIBODY; PARATHYROID HORMONE[1-34]; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM RANELATE; THIOPHENE DERIVATIVE;

BONE DEVELOPMENT; BONE DISEASES; DRUG EFFECTS; FEMALE; HUMAN; MALE;

ANTIBODIES, MONOCLONAL, HUMANIZED; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES; DIPHOSPHONATES; FEMALE; HUMANS; MALE; OSTEOGENESIS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TERIPARATIDE; THIOPHENES;

EID: 84903318590     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.6061/clinics/2014(06)12     Document Type: Review

References (141)

1. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93(2):165-76. http://dx.doi.org/10.1016/S0092-8674(00)81569-X
2. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology. 2001;142(12):5050-5. http://dx.doi.org/10.1210/endo.142.12.8536
3. Collin-Osdoby P. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res. 2004;95(11): 1046-57. http://dx.doi.org/10.1161/01.RES.0000149165.99974.12
4. Silvestrini G, Ballanti P, Patacchioli F, Leopizzi M, Gualtieri N, Monnazzi P, et al. Detection of osteoprotegerin (OPG) and its ligand (RANKL) mRNA and protein in femur and tibia of the rat. J Mol Histol. 2005;36(1-2):59-67. http://dx.doi.org/10.1007/s10735-004-3839-1
5. Nakashima T, Hayashi M, Fukunaga T, Kurata K, Oh-Hora M, Feng QJ, et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med. 2011;17(10):1231-4. http://dx.doi.org/10.1038/nm.2452
6. Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A. 1999;96(7):3540-5. http://dx.doi.org/10.1073/pnas.96.7.3540
7. Fonseca JE Rebalancing bone turnover in favour of formation with strontium ranelate: Implications for bone strength. Rheumatology (Oxford). 2008;47 Suppl 4:iv17-19
8. Boyce BF, Xing L. Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther. 2007;9 Suppl 1:S1. http://dx.doi.org/10.1186/ar2165
9. Hofbauer LC, Heufelder AE Role of receptor activator of nuclear factorkappa B ligand and osteopr otegerin in bone cell biology. J Mol Med. 2001;79(5-6):243-53. http://dx.doi.org/10.1007/s001090100226
10. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423(6937):337-42. http://dx.doi.org/10.1038/nature01658
11. Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA. 2004;292(4):490-5. http://dx.doi.org/10.1001/jama.292.4.490
12. Eggelmeijer F, Papapoulos SE, Van Paassen HC, Dijkmans BA, Breedveld FC. Clinical and biochemical response to single infusion of pamidronate in patients with active rheumatoid arthritis: a double blind placebo controlled study. J Rheumatol. 1994;21(11):2016-20
13. Lala R, Matarazzo P, Bertelloni S, Buzi F, Rigon F, De Sanctis C. Pamidronate treatment of bone fibrous dysplasia in nine children with McCune-Albright sindrome. Acta Paediatr. 2000;89(2):188-93. http://dx.doi.org/10.1111/j.1651-2227.2000.tb01214.x.
14. Rodan GA, Martin TJ Therapeutic approaches to bone diseases. Science. 2000;289(5484):1508-14. http://dx.doi.org/10.1126/science.289.5484.1508
15. Lane JM, Khan SN, O'Connor WJ, Nydick M, Hommen JP, Schneider R, Tomin E, et al. Bisphosphonate therapy in fibrous dysplasia. Clin Orthop. 2001;(382):6-12. http://dx.doi.org/10.1097/00003086-200101000-00003
16. Tassone P, Tagliaferri P, Viscomi C, Palmieri C, Caraglia M, D'Alessandro A, et al. Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro. Br J Cancer. 2003;88(12):1971-8
17. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer. 2000;88(12 Suppl):2961-78. http://dx.doi.org/10.1002/1097-0142(20000615)88:12+,2961::AID-CNCR12.3.0.CO;2-L.
18. Jung A, Bisaz S, Fleisch H. The binding of pyrophosphate and two diphosphonates on hydroxyapatite crystals. Calcif Tissue Res. 1973;11(4):269-80. http://dx.doi.org/10.1007/BF02547227
19. Sudhoff H, Jung JY, Ebmeyer J, Faddis BT, Hildmann H, Chole RA. Zoledronic acid inhibits osteoclastogenesis in vitro and in a mouse model of inflammatory osteolysis. Ann Otol Rhinol Laryngol. 2003;112(9 Pt 1):780-6
20. Evdokiou A, Labrinidis A, Bouralexis S, Hay S, Findlay DM. Induction of cell death of human osteogenic sarcoma cells by zoledronic acid resembles anoikis. Bone. 2003;33(2):216-28. http://dx.doi.org/10.1016/S8756-3282(03)00223-0
21. Green JR. Bisphosphonates: preclinical review. Oncologist. 2004;9 Suppl 4:3-13. http://dx.doi.org/10.1634/theoncologist.9-90004-3
22. Rodan GA, Reszka AA. Bisphosphonate mechanism of action. Curr Mol Med. 2002;2(6):571-7. http://dx.doi.org/10.2174/1566524023362104
23. D'Aoust P, McCulloch CA, Tenenbaum HC, Lekic PC. Etidronate (HEBP) promotes osteoblast differentiation and wound closure in rat calvaria. Cell Tissue Res. 2000;302(3):353-63. http://dx.doi.org/10.1007/s004419900165
24. Hughes D.E., MacDonald BR, Russell RGG, and Gowen M. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest. 1989;83(6):1930-5. http://dx.doi.org/10.1172/JCI114100
25. Von Knoch F, Jaquiery C, Kowalsky M, Schaeren S, Alabre C, Martin I, et al. Effects of bisphosphonates on proliferation and osteoblast differentiation of human bone marrow stromal cells. Biomaterials. 2005;26(34):6941-9. http://dx.doi.org/10.1016/j.biomaterials.2005.04.059
26. Still K, Phipps RJ, Scutt A. Effects of risedronate, alendronate, and etidronate on the viability and activity of rat bone marrow stromal cells in vitro. Calcif Tissue Int. 2003;72(2):143-50. http://dx.doi.org/10.1007/s00223-001-2066-y.
27. Reinholz GG, Getz B, Sanders ES, Karpeisky MY, Padyukova NS, Mikhailov SN, et al. Distinct mechanisms of bisphosphonate action between osteoblasts and breast cancer cells: identity of a potent new bisphosphonate analogue. Breast Cancer Res Treat. 2002;71(3):257-68. http://dx.doi.org/10.1023/A:1014418017382
28. Reinholz GG, Getz B, Pederson L, Sanders ES, Subramaniam M, Ingle JN, et al. Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res. 2000;60(21):6001-7
29. Sahni M, Guenther HL, Fleisch H, Collin P, Martin TJ. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest. 1993;91(5):2004-11. http://dx.doi.org/10.1172/JCI116422
30. Nishikawa M, Akatsu T, Katayama Y, Yasutomo Y, Kado S, Kugal N, et al. Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures. Bone. 1996;18(1):9-14. http://dx.doi.org/10.1016/8756-3282(95)00426-2
31. Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest. 1999;104(10):1363-74. http://dx.doi.org/10.1172/JCI6800
32. Y Abe Y, Kawakami A, Nakashima T, Ejima E, Fujiyama K, Kiriyama T, et al. Etidronate inhibits human osteoblast apoptosis by inhibition of pro-apoptotic factor(s) produced by activated T cells. J Lab Clin Med. 2000;136(5):344-54. http://dx.doi.org/10.1067/mlc.2000.109757
33. Giuliani N, Pedrazzoni M, Passeri G, Girasole G. Bisphosphonates inhibit IL-6 production by human osteoblast-like cells. Scand. J. Rheumatol. 1998;27(1):38-41
34. Itoh F, Aoyagi S, Furihata-Komatsu H, Aoki M, Kusama H, Kojima M, et al. Clodronate stimulates osteoblast differentiation in ST2 and MC3T3-E1 cells and rat organ cultures. Eur J Pharmacol. 2003;477(1): 9-16
35. Viereck V, Emons G, Lauck V, Frosch KH, Blaschke S, Grundker C, et al. Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun. 2002;291(3):680-6. http://dx.doi.org/10.1006/bbrc.2002.6510
36. Pan B, Farrugia AN, To LB, Findlay DM, Green J, Lynch K, et al. The nitrogencontaining bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblastlike cells by activating TNF-alpha converting enzyme (TACE). J Bone Miner Res. 2004;19(1):147-54. http://dx.doi.org/10.1359/jbmr.2004.19.1.147
37. Im GI, Qureshi SA, Kenney J, Rubash HE, Shanbhag AS. Osteoblast proliferation and maturation by bisphosphonates. Biomaterials. 2004;25(18):4105-15. http://dx.doi.org/10.1016/j.biomaterials.2003.11.024
38. Xiong Y, Yang HJ, Feng J, Shi ZL, Wu LD. Effects of alendronate on the proliferation and osteogenic differentiation of MG-63 cells. J Int Med Res. 2009;37(2):407-16
39. Giuliani N, Pedrazzoni M, Negri G, Passeri G, Impicciatore M, Girasole G. Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo. Bone. 1998;22(5):455-61. http://dx.doi.org/10.1016/S8756-3282(98) 00033-7
40. Klein BY, Ben-Bassat H, Breuer E, Solomon V, Golomb G, Structurally different bisphosphonates exert opposing effects on alkaline. J Cell Biochem. 1998;68(2):186-94. http://dx.doi.org/10.1002/(SICI)1097-4644(19980201)68:2,186::AID-JCB5.3.0.CO;2-R.
41. Kim HK, Kim JH, Abbas AA, Yoon TR. Alendronate enhances osteogenic differentiation of bone marrow stromal cells: a preliminary study. Clin Orthop Relat Res. 2009;467(12):3121-8. http://dx.doi.org/10.1007/s11999-008-0409-y
42. Pan B, To LB, Farrugia AN, Findlay DM, Green J, Gronthos S, et al. The nitrogen-containing bisphosphonate, zoledronic acid, increases mineralisation of human bone-derived cells in vitro. Bone. 2004;34(1):112-23. http://dx.doi.org/10.1016/j.bone.2003.08.013
43. Idris AI, Rojas J, Greig IR, Van't Hof RJ, Ralston SH. Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro. Calcif Tissue Int. 2008;82(3):191-201. http://dx.doi.org/10.1007/s00223-008-9104-y.
44. Orriss IR, Key ML, Colston KW, Arnett TR. Inhibition of osteoblast function in vitro by aminobisphosphonates. J Cell Biochem. 2009; 106(1):109-18. http://dx.doi.org/10.1002/jcb.21983
45. Bellido T, Plotkin LI. Novel actions of bisphosphonates in bone: preservation of osteoblast and osteocyte viability. Bone. 2011;49(1):50-5. http://dx.doi.org/10.1016/j.bone.2010.08.008
46. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809-22
47. Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab. 2000;85(11):4118-24. http://dx.doi.org/10.1210/jcem.85.11.6953
48. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med. 2001;344(5):333-40
49. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA. 1999;282(14):1344-52. http://dx.doi.org/10.1001/jama.282.14.1344
50. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006;296(24):2927-38. http://dx.doi.org/10.1001/jama.296.24.2927
51. Rizzoli R, Burlet N, Cahall D, Delmas PD, Eriksen EF, Felsenberg D, et al. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone. 2008;42(5):841-7. http://dx.doi.org/10.1016/j.bone.2008.01.003
52. Rizzoli R, Akesson K, Bouxsein M, Kanis JA, Napoli N, Papapoulos S, et al. Subtrochanteric fractures after long-term treatment with bisphosphonates: a european society on clinical and economic aspects of osteoporosis and osteoarthritis, and international osteoporosis foundation working group report. Osteoporos Int. 2011;22(2):373-90. http://dx.doi.org/10.1007/s00198-010-1453-5
53. Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010;25(11):2267-94. http://dx.doi.org/10.1002/jbmr. 253
54. Body JJ, Greipp P, Coleman RE, Facon T, Geurs F, Fermand JP, et al. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer. 2003;97(3 Suppl):887-92. http://dx.doi.org/10.1002/cncr.11138
55. Stolina M, Adamu S, Ominsky MS, Dzamba BJ, Asuncion F, Geng Z, et al. RANKL is a marker and mediator of local and systemic bone loss in two rat models of inflammatory arthritis. J Bone Miner Res 2005;20(10):1756-65. http://dx.doi.org/10.1359/JBMR.050601
56. Padagas J, Colloton M, Shalhoub V, Kostenuik PJ, Morony S, Munyakazi L, et al. The receptor activator of nuclear factor-kB ligand inhibitor osteoprotegerin is a bone-protective agent in a rat model of chronic renal insufficiency and hyperparathyroidism. Calcif Tissue Int 2006;78(1):35-44. http://dx.doi.org/10.1007/s00223-005-0161-1
57. Kim H, Morgan-Bagley S, Kostenuik PJ. RANKL inhibition: A novel strategy to decrease femoral head deformity after ischemic necrosis. J Bone Miner Res. 2006;21(12):1946-54. http://dx.doi.org/10.1359/jbmr. 060905
58. Ominsky MS, Kostenuik PJ, Cranmer P, Smith SY, Atkinson JE. The RANKL inhibitor OPG-Fc increases cortical and trabecular bone mass in intact cynomolgus monkeys. Osteoporos Int 2007;18(8):1073-82. http://dx.doi.org/10.1007/s00198-007-0363-7
59. Bekker PJ, Holloway D, Nakanishi A, Arrighi M, Leese PT, Dunstan CR. The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res. 2001;16(2):348-60. http://dx.doi.org/10.1359/jbmr.2001.16.2.348
60. European Public Assessment Report. Available at http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001120/human_med_001324.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d124 (last accessed 2011).
61. Rizzoli R, Yasothan U, Kirkpatrick P. Denosumab. Nat Rev Drug Discov 2010;9(8):591-2. http://dx.doi.org/10.1038/nrd3244
62. Belavic JM. Denosumab (Prolia): a new option in the treatment of osteoporosis. Nurse Pract. 2011;36(1):11-2. http://dx.doi.org/10.1097/01.NPR.0000391178.47878.73
63. Lipton A, Goessl C. Clinical development of anti-RANKL therapies for treatment and prevention of bone metastasis. Bone. 2011;48(1):96-9. http://dx.doi.org/10.1016/j.bone.2010.10.161
64. Miller PD, Bolognese MA, Lewiecki EM, McClung MR, Ding B, Austin M, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 2008;43(2):222-9. http://dx.doi.org/10.1016/j.bone. 2008.04.007
65. Lewiecki EM. Treatment of osteoporosis with denosumab. Maturitas. 2010;66(2):182-6. http://dx.doi.org/10.1016/j.maturitas.2010.02.008
66. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756-65
67. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006;354(8):821-31
68. Body JJ, Facon T, Coleman RE, Lipton A, Geurs F, Fan M, et al. A study of the biological receptor activator of nuclear factor-kB ligant inhibitor, Denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res. 2006;12(4):1221-8. http://dx.doi.org/10.1158/1078-0432.CCR-05-1933
69. Khajuria DK, Razdan R, Mahapatra DR. Drugs for the management of osteoporosis: a review. Rev Bras Reumatol. 2011;51(4):365-71
70. Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest. 2003;111(8):1221-30. http://dx.doi.org/10.1172/JCI200317215
71. Bord S, Ireland DC, Beavan SR, Compston JE. The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts. Bone. 2003;32(2):136-41. http://dx.doi.org/10.1016/S8756-3282(02)00953-5
72. McKane WR, Khosla S, Burritt MF, Kao PC, Wilson DM, Ory SJ, et al. Mechanism of renal calcium conservation with estrogen replacement therapy in women in early postmenopause -a clinical research center study. J Clin Endocrinol Metab. 1995;80(12):3458-64
73. Gennari C, Agnusdei D, Nardi P, Civitelli R. Estrogen preserves a normal intestinal responsiveness to 1,25-dihydroxyvitamin D3 in oophorectomized women. J Clin Endocrinol Metab. 1990;71(5):1288-93. http://dx.doi.org/10.1210/jcem-71-5-1288
74. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90(18):1371-88. http://dx.doi.org/10.1093/jnci/90.18.1371
75. Cosman F, Lindsay R. Selective estrogen receptor modulators: Clinical spectrum. Endocr Rev. 1999;20(3):418-34
76. Muchmore DB. Raloxifene: A Selective Estrogen Receptor Modulator (SERM) with Multiple Target System Effects. Oncologist. 2000;5(5):388-92. http://dx.doi.org/10.1634/theoncologist.5-5-388
77. Luvizuto ER, Queiroz TP, Dias SM, Okamoto T, Dornelles RC, Garcia IR Jr, et al. Histomorphometric analysis and immunolocalization of RANKL and OPG during the alveolar healing process in female ovariectomized rats treated with oestrogen or raloxifene. Arch Oral Biol. 2010;55: 52-9. http://dx.doi.org/10.1016/j.archoralbio.2009.11.001
78. Olivier S, Fillet M, Malaise M, Piette J, Bours V, Merville MP, et al. Sodium nitroprusside-induced osteoblast apoptosis is mediated by long chain ceramide and is decreased by raloxifene. Biochem Pharmacol. 2005;69(6):891-901. http://dx.doi.org/10.1016/j.bcp.2004.11.030
79. Taranta A, Brama M, Teti A, De luca V, Scandurra R, Spera G, Agnusdeiet al. The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro. Bone 2002;30(2): 368-76. http://dx.doi.org/10.1016/S8756-3282(01)00685-8
80. Viereck V, Grundker C, Blaschke S, Niederkleine B, Siggelkow H, Frosch KH, et al. Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts. J Clin Endocrinol Metab. 2003;88(9):4206-13. http://dx.doi.org/10.1210/jc.2002-021877
81. Kawamoto S, Ejiri S, Nagaoka E, Ozawa H. Effects of oestrogen deficiency on osteoclastogenesis in the rat periodontium. Arch Oral Bio. 2002;47(1):67-73. http://dx.doi.org/10.1016/S0003-9969(01)00086-3
82. Michael HL, Härkönen PL, Kangas L, Väänänen HK, Hentunen TA. Differential effects of selective oestrogen receptor modulators (SERMs) tamoxifen, ospemifene and raloxifene on human osteoclasts in vitro. Br J Pharmacol. 2007;151(3):384-95
83. Noda-Seino H, Sawada K, Hayakawa J, Ohyagi-Hara C, Mabuchi S, Takahashi K, et al. Estradiol and Raloxifene induce the proliferation of osteoblasts through G-protein-coupled receptor GPR30. J Endocrinol Invest. 2013;36(1):21-7
84. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434-41
85. Brown EM, Gamba G, Riccardi D, Lombardi M, Butters R, Kifor O, et al. Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature. 1993;366(6455):575-80. http://dx.doi.org/10.1038/366575a0
86. Jilka RL. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone. 2007;40(6):1434-46. http://dx.doi.org/10.1016/j.bone.2007.03.017
87. Bukata SV, Puzas JE. Orthopedic uses of teriparatide. Curr Osteoporos Rep. 2010;8(1):28-33. http://dx.doi.org/10.1007/s11914-010-0006-3
88. Andreassen TT, Ejersted C, Oxlund H. Intermittent parathyroid hormone (1-34) treatment increases callus formation and mechanical strength of healing rat fractures. J Bone Miner Res. 1999;14(6):960-8. http://dx.doi.org/10.1359/jbmr.1999.14.6.960
89. Compston JE. Skeletal actions of intermittent parathyroid hormone: effects on bone remodelling and structure. Bone. 2007;40(6):1447-52. http://dx.doi.org/10.1016/j.bone.2006.09.008
90. Kaback LA, Soung do Y, Naik A, Geneau G, Schwarz EM, Rosier RN, et al. Teriparatide (1-34 human PTH) regulation of osterix during fracture repair. J Cell Biochem. 2008;105(1):219-26. http://dx.doi.org/10.1002/jcb.21816
91. Nakajima A, Shimoji N, Shiomi K, Shimizu S, Moriya H, Einhorn TA, et al. Mechanisms for the enhancement of fracture healing in rats treated with intermittent low-dose human parathyroid hormone (1-34). J Bone Miner Res. 2002;17(11):2038-47. http://dx.doi.org/10.1359/jbmr. 2002.17.11.2038
92. Nakazawa T, Nakajima A, Shiomi K, Moriya H, Einhorn TA, Yamazaki M. Effects of low-dose, intermittent treatment with recombinant human parathyroid hormone (1-34) on chondrogenesis in a model of experimental fracture healing. Bone. 2005;37(5):711-9. http://dx.doi.org/10.1016/j.bone.2005.06.013
93. Bukata SV, Puzas JE. Orthopedic Uses of Teriparatide. Curr Osteoporos Rep. 2010;8(1):28-33. http://dx.doi.org/10.1007/s11914-010-0006-3
94. Kakar S, Einhorn TA, Vora S, Miara LJ, Hon G, Wigner NA, et al. Enhanced chondrogenesis and Wnt signaling in PTH-treated fractures. Journal of bone and mineral research. J Bone Miner Res. 2007;22(12):1903-12. http://dx.doi.org/10.1359/jbmr.070724
95. Hodsman AB, Bauer DC, Dempster DW, Dian L, Hanley DA, Harris ST, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev. 2005;26(5):688-703. http://dx.doi.org/10.1210/er. 2004-0006
96. Subbiah V, Madsen VS, Raymond AK, Benjamin RS, Ludwig JA. Of mice and men: divergent risks of teriparatide-induced osteosarcoma. Osteoporos Int. 2010;21(6):1041-5. http://dx.doi.org/10.1007/s00198-009-1004-0
97. Saag KG, Shane E, Boonen S, Marin F, Donley DW, Taylor KA, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007;357(20):2028-39
98. Vahle JL, Long GG, Sandusky G, Westmore M, Ma YL, Sato M. Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose. Toxicol Pathol. 2004;32(4):426-38
99. Wilker C, Jolette J, Smith S, Doyle N, Hardisty J, Metcalfe AJ, et al. A no observable carcinogenic effect dose level identified in Fischer 344 rats following daily treatment with PTH(1-84) for 2 years: role of the Cterminal PTH receptor?. J Bone Miner Res. 2004;19 Supp 1:SA435
100. Ryder KM, Tanner SB, Carbone L, Williams JE, Taylor HM, Bush A, et al. Teriparatide is safe and effectively increases bone biomarkers in institutionalized individuals with osteoporosis. J Bone Miner Metab. 2010;28(2):233-9. http://dx.doi.org/10.1007/s00774-009-0123-1
101. Losada B, Zanchetta J, Zerbini C, Molina J, de la Pena P, Liu C, et al. Active comparator trial of teriparatide vs alendronate for treating glucocorticoid-induced osteoporosis: results from the Hispanic and non-Hispanic cohorts. J Clin Densitom. 2009;12(1):63-70. http://dx.doi.org/10.1016/j.jocd.2008.10.002
102. Harper KD, Krege JH, Marcus R, Mitlak BH. Osteosarcoma and teriparatide? J Bone Miner Res. 2007;22(2):334
103. Cesareo R, Napolitano C, Iozzino M. Strontium ranelate in postmenopausal osteoporosis treatment: a critical appraisal. Int J Womens Health. 2010;2:1-6
104. Roux C, Fechtenbaum J, Kolta S, Isaia G, Andia JB, Devogelaer JP. Strontium ranelate reduces the risk of vertebral fracture in young postmenopausal women with severe osteoporosis. Ann Rheum Dis. 2008;67(12):1736-8. http://dx.doi.org/10.1136/ard.2008.094516
105. Marie P. Strontium ranelate: a novel mode of action optimizing bone formation and resorption. Osteoporos Int. 2005;16:7-10. http://dx.doi.org/10.1007/s00198-004-1753-8
106. Brennan TC, Rybchyn MS, Green W, Atwa S, Conigrave AD, Mason RS. Osteoblasts play key roles in the mechanisms of action of strontium ranelate. Br J Pharmacol. 2009;157(7):1291-1300
107. Marie PJ. Strontium ranelate: new insights into its dual mode of action. Bone. 2007;40-S5-8
108. Bonnelye E, Chabadel A, Saltel F, Jurdic P. Dual effect of strontium ranelate: stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro. Bone. 2008;42(1):129-38. http://dx.doi.org/10.1016/j.bone.2007.08.043
109. Baron R, Tsouderos Y. In vitro effects of S12911-2 on osteoclast function and bone marrow macrophage differentiation. Eur J Pharmacol. 2002;450(1):11-7
110. Takahashi N, Sasaki T, Tsouderos Y, Suda T. S 12911-2 Inhibits osteoclastic bone resorption in vitro. J Bone Miner Res. 2003;18(6):1082-7. http://dx.doi.org/10.1359/jbmr.2003.18.6.1082
111. Mentaverri R, Hurtel AS, Kamel S, Robin B, Brazier M. Extracellular concentrations of strontium directly stimulates osteoclast apoptosis. J Bone Min Res. 2003;18:M237. http://dx.doi.org/10.1359/jbmr.2003.18.2.237
112. Chattopadhyay N, Quinn SJ, Kifor O, Ye C, Brown EM. The calciumsensing receptor (CaR) is involved in strontium ranelate-induced osteoblast proliferation. Biochem Pharmacol. 2007;74(3):438-47. http://dx.doi.org/10.1016/j.bcp.2007.04.020
113. Zhu LL, Zaidi S, Peng Y, Zhou H, Moonga BS, Blesius A, et al. Induction of a program gene expression during osteoblast differentiation with strontium ranelate. Biochem Biophys Res Commun. 2007;355(2):307-11. http://dx.doi.org/10.1016/j.bbrc.2007.01.120
114. Sila-Asna M, Bunyaratvej A, Maeda S, Kitaguchi H, Bunyaratavej N. Osteoblast Differentiation and Bone Formation Gene Expression in Strontium-inducing Bone Marrow Mesenchymal Stem Cell. Kobe J Med Sci. 2007;53(1-2):25-35
115. Hao Y, Yan H, Wang X, Zhu B, Ning C, Ge S. Evaluation of osteoinduction and proliferation on nano-Sr-HAP: a novel orthopedic biomaterial for bone tissue regeneration. J Nanosci Nanotechnol. 2012;12(1):207-12. http://dx.doi.org/10.1166/jnn.2012.5125
116. Ni GX, Yao ZP, Huang GT, Liu WG, Lu WW. The effect of strontium incorporation in hydroxyapatite on osteoblasts in vitro. J Mater Sci Mater Med. 2011;22(4):961-7. http://dx.doi.org/10.1007/s10856-011-4264-0
117. Isaac J, Nohra J, Lao J, Jallot E, Nedelec JM, Berdal A, et al. Effects of strontium-doped bioactive glass on the differentiation of cultured osteogenic cells. Eur Cell Mater. 2011;21:130-43
118. Liu F, Zhang X, Yu X, Xu Y, Feng T, Ren D. In vitro study in stimulating the secretion of angiogenic growth factors of strontium-doped calcium polyphosphate for bone tissue engineering. J Mater Sci Mater Med. 2011;22(3):683-92. http://dx.doi.org/10.1007/s10856-011-4247-1
119. Zhang W, Shen Y, Pan H, Lin K, Liu X, Darvell BW, et al. Effects of strontium in modified biomaterials. Acta Biomater. 2011;7(2):800-8. http://dx.doi.org/10.1016/j.actbio.2010.08.031
120. Nardone V, Fabbri S, Marini F, Zonefrati R, Galli G, Carossino A, et al. Osteodifferentiation of human preadipocytes induced by strontium released from hydrogels. Int J Biomater. 2012;2012:865-291
121. Krishnan V, Bryant HU, Macdougald OA. Regulation of bone mass by Wnt signalling. J Clin Invest. 2006;116(5):1202-9. http://dx.doi.org/10.1172/JCI28551
122. Bodine PV and Komm BS. Wnt signaling and osteoblastogenesis. Rev Endocr Metab Disord. 2006;7(1-2):33-9
123. Qiu W, Andersen TE, Bollerslev J, Mandrup S, Abdallah BM, Kassem M. Patients with high bone mass phenotype exhibit enhanced osteoblast differentiation and inhibition of adipogenesis of human mesenchymal stem cells. J Bone Miner Res. 2007;22(11):1720-31. http://dx.doi.org/10.1359/jbmr.070721
124. Baron R, Rawadi G. Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology. 2007;148(6):2635-43. http://dx.doi.org/10.1210/en.2007-0270
125. Manolagas SC & Almeida M. Gone with the Wnts: beta-catenin, T-cell factor, forkhead box O, and oxidative stress in age-dependent diseases of bone, lipid, and glucose metabolism. Molecular Endocrinology. 2007; 21(11):2605-14. http://dx.doi.org/10.1210/me.2007-0259
126. Clément-Lacroix P, Ai M, Morvan F, Roman-Roman S, Vayssière B, Belleville C, et al. Lrp5-independent activation of Wnt signaling by lithium chloride increases bone formation and bone mass in mice. Proc Natl Acad Sci U S A. 2005;102(48):17406-11. http://dx.doi.org/10.1073/pnas.0505259102
127. Kulkarni NH, Onyia JE, Zeng Q, Tian X, Liu M, Halladay DL, Frolik CA et al. Orally bioavailable GSK-3alpha/beta dual inhibitor increases markers of cellular differentiation in vitro and bone mass in vivo. J Bone Miner Res. 2006;21(6):910-20. http://dx.doi.org/10.1359/jbmr.060316
128. Marie PJ, Kassem M. Osteoblasts in osteoporosis: past, emerging, and future anabolic targets. Eur J Endocrinol. 2011;165(1):1-10
129. Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D'Agostin D, et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res. 2008;23(6):860-9. http://dx.doi.org/10.1359/jbmr.080216
130. Rey JP, Ellies DL. Wnt modulators in the biotech pipeline. Dev Dyn. 2010;239(1):102-14
131. Enders GH. Wnt therapy for bone loss: golden goose or Trojan horse?. J Clin Invest. 2009;119(4):758-60. http://dx.doi.org/10.1172/JCI38973
132. Morvan F, Boulukos K, Clément-Lacroix P, Roman Roman S, Suc-Royer I, Vayssière B, et al. Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J Bone Miner Res. 2006;21(6):934-45. http://dx.doi.org/10.1359/jbmr.060311
133. Li J, Sarosi I, Cattley RC, Pretorius J, Asuncion F, Grisanti M, et al. Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone. 2006;39(4):754-66. http://dx.doi.org/10.1016/j.bone. 2006.03.017
134. Guo J, Liu M, Yang D, Bouxsein ML, Saito H, Galvin RJ, et al. Suppression of Wnt signaling by Dkk1 attenuates PTH-mediated stromal cell response and new bone formation. Cell Metab. 2010; 11(2):161-71. http://dx.doi.org/10.1016/j.cmet.2009.12.007
135. Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res. 2009;24(4):578-88. http://dx.doi.org/10.1359/jbmr.081206
136. Padhi D, Jang G, Stouch B, Fang L, Posvar E. Single-dose, placebocontrolled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. 2011;26(1):19-26. http://dx.doi.org/10.1002/jbmr.173
137. Ominsky MS, Vlasseros F, Jolette J, Smith SY, Stouch B, Doellgast G, et al. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res. 2010;25(5):948-59. http://dx.doi.org/10.1002/jbmr. 14
138. Li X, Warmington KS, Niu QT, Asuncion FJ, Barrero M, Grisanti M, et al. Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats. J Bone Miner Res. 2010;25(12):2647-56. http://dx.doi.org/10.1002/jbmr.182
139. Cipriano CA, Issack PS, Shindle L, Werner CM, Helfet DL, Lane JM. Recent advances toward the clinical application of PTH (1-34) in fracture healing. HSS J. 2009;5(2):149-53
140. Arlot M, Meunier PJ, Boivin G, Haddock L, Tamayo J, Correa-Rotter R, et al. Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. Bone Miner Res. 2005;20(7):1244-53. http://dx.doi.org/10.1359/JBMR.050309
141. Briot K, Benhamou CL, Roux C. Hip cortical thickness assessment in postmenopausal women with osteoporosis and strontium ranelate effect on hip geometry. J Clin Densitom. 2012;15(2):176-85. http://dx.doi.org/10.1016/j.jocd.2011.11.006.